Inflammatory and Physiological Consequences of Debridement of Fibrous Tissue after Volumetric Muscle Loss Injury

Benjamin T. Corona; Jessica C. Rivera; Sarah M. Greising

doi:10.1111/cts.12519

Inflammatory and Physiological Consequences of Debridement of Fibrous Tissue after Volumetric Muscle Loss Injury

Benjamin T. Corona, Jessica C. Rivera, Sarah M. Greising

Kinesiology

Research output: Contribution to journal › Article › peer-review

30 Scopus citations

Abstract

Volumetric muscle loss (VML) injuries present chronic loss of muscle fibers followed by expansive fibrotic tissue deposition. Regenerative medicine therapies are under development to promote regeneration. However, mitigation of the expansive fibrous tissue is required for integration with the remaining muscle. Using a porcine VML model, delayed debridement of injury fibrosis was performed 3 months post-VML and observed for an additional 4 weeks. A second group underwent the initial VML and was observed for 4 weeks, allowing comparison of initial fibrosis formation and debrided groups. The following salient observations were made: (i) debridement neither exacerbated nor ameliorated strength deficits; (ii) debridement results in recurrent fibrotic tissue deposition of a similar magnitude and composition as acute VML injury; and (iii) similarly upregulated transcriptional fibrotic and transcriptional pathways persist 4 weeks after initial VML or delayed debridement. This highlights the need for future studies to investigate adjunctive antifibrotic treatments for the fibrosed musculature.

Original language	English (US)
Pages (from-to)	208-217
Number of pages	10
Journal	Clinical and Translational Science
Volume	11
Issue number	2
DOIs	https://doi.org/10.1111/cts.12519
State	Accepted/In press - Jan 1 2017

Bibliographical note

Funding Information:
We gratefully acknowledge the USAISR Veterinary Support and Comparative Pathology Branches, Monica Jalomo, and Javier Chapa for technical assistance in the completion of these studies. Studies were funded through the Congressionally Directed Medical Research Program (Award #MR140099 awarded to B.T.C.). The opinions or assertions contained herein are the private views of the authors and are not to be construed as official or as reflecting the views of the Department of the Army, the Department of Defense, or the United States Government. B.T.C. and S.M.G. wrote the manuscript. B.T.C. and S.M.G. designed the research. B.T.C., J.C.R., and S.M.G. performed the research. B.T.C. and S.M.G. analyzed the data.

Funding Information:
Source of Funding. Studies were funded through the Congressionally Directed Medical Research Program (Award #MR140099 awarded to B.T.C.).

Publisher Copyright:
© 2017 The Authors. Clinical and Translational Science published by Wiley Periodicals, Inc. on behalf of American Society for Clinical Pharmacology and Therapeutics

PubMed: MeSH publication types

Journal Article

Access

10.1111/cts.12519

Cite this

@article{f17d5ad9054f4a4ba75c042b9a4d0fb7,

title = "Inflammatory and Physiological Consequences of Debridement of Fibrous Tissue after Volumetric Muscle Loss Injury",

abstract = "Volumetric muscle loss (VML) injuries present chronic loss of muscle fibers followed by expansive fibrotic tissue deposition. Regenerative medicine therapies are under development to promote regeneration. However, mitigation of the expansive fibrous tissue is required for integration with the remaining muscle. Using a porcine VML model, delayed debridement of injury fibrosis was performed 3 months post-VML and observed for an additional 4 weeks. A second group underwent the initial VML and was observed for 4 weeks, allowing comparison of initial fibrosis formation and debrided groups. The following salient observations were made: (i) debridement neither exacerbated nor ameliorated strength deficits; (ii) debridement results in recurrent fibrotic tissue deposition of a similar magnitude and composition as acute VML injury; and (iii) similarly upregulated transcriptional fibrotic and transcriptional pathways persist 4 weeks after initial VML or delayed debridement. This highlights the need for future studies to investigate adjunctive antifibrotic treatments for the fibrosed musculature.",

author = "Corona, {Benjamin T.} and Rivera, {Jessica C.} and Greising, {Sarah M.}",

note = "Funding Information: We gratefully acknowledge the USAISR Veterinary Support and Comparative Pathology Branches, Monica Jalomo, and Javier Chapa for technical assistance in the completion of these studies. Studies were funded through the Congressionally Directed Medical Research Program (Award #MR140099 awarded to B.T.C.). The opinions or assertions contained herein are the private views of the authors and are not to be construed as official or as reflecting the views of the Department of the Army, the Department of Defense, or the United States Government. B.T.C. and S.M.G. wrote the manuscript. B.T.C. and S.M.G. designed the research. B.T.C., J.C.R., and S.M.G. performed the research. B.T.C. and S.M.G. analyzed the data. Funding Information: Source of Funding. Studies were funded through the Congressionally Directed Medical Research Program (Award #MR140099 awarded to B.T.C.). Publisher Copyright: {\textcopyright} 2017 The Authors. Clinical and Translational Science published by Wiley Periodicals, Inc. on behalf of American Society for Clinical Pharmacology and Therapeutics",

year = "2017",

month = jan,

day = "1",

doi = "10.1111/cts.12519",

language = "English (US)",

volume = "11",

pages = "208--217",

journal = "Clinical and Translational Science",

issn = "1752-8054",

publisher = "Wiley-Blackwell",

number = "2",

}

TY - JOUR

T1 - Inflammatory and Physiological Consequences of Debridement of Fibrous Tissue after Volumetric Muscle Loss Injury

AU - Corona, Benjamin T.

AU - Rivera, Jessica C.

AU - Greising, Sarah M.

N1 - Funding Information: We gratefully acknowledge the USAISR Veterinary Support and Comparative Pathology Branches, Monica Jalomo, and Javier Chapa for technical assistance in the completion of these studies. Studies were funded through the Congressionally Directed Medical Research Program (Award #MR140099 awarded to B.T.C.). The opinions or assertions contained herein are the private views of the authors and are not to be construed as official or as reflecting the views of the Department of the Army, the Department of Defense, or the United States Government. B.T.C. and S.M.G. wrote the manuscript. B.T.C. and S.M.G. designed the research. B.T.C., J.C.R., and S.M.G. performed the research. B.T.C. and S.M.G. analyzed the data. Funding Information: Source of Funding. Studies were funded through the Congressionally Directed Medical Research Program (Award #MR140099 awarded to B.T.C.). Publisher Copyright: © 2017 The Authors. Clinical and Translational Science published by Wiley Periodicals, Inc. on behalf of American Society for Clinical Pharmacology and Therapeutics

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Volumetric muscle loss (VML) injuries present chronic loss of muscle fibers followed by expansive fibrotic tissue deposition. Regenerative medicine therapies are under development to promote regeneration. However, mitigation of the expansive fibrous tissue is required for integration with the remaining muscle. Using a porcine VML model, delayed debridement of injury fibrosis was performed 3 months post-VML and observed for an additional 4 weeks. A second group underwent the initial VML and was observed for 4 weeks, allowing comparison of initial fibrosis formation and debrided groups. The following salient observations were made: (i) debridement neither exacerbated nor ameliorated strength deficits; (ii) debridement results in recurrent fibrotic tissue deposition of a similar magnitude and composition as acute VML injury; and (iii) similarly upregulated transcriptional fibrotic and transcriptional pathways persist 4 weeks after initial VML or delayed debridement. This highlights the need for future studies to investigate adjunctive antifibrotic treatments for the fibrosed musculature.

AB - Volumetric muscle loss (VML) injuries present chronic loss of muscle fibers followed by expansive fibrotic tissue deposition. Regenerative medicine therapies are under development to promote regeneration. However, mitigation of the expansive fibrous tissue is required for integration with the remaining muscle. Using a porcine VML model, delayed debridement of injury fibrosis was performed 3 months post-VML and observed for an additional 4 weeks. A second group underwent the initial VML and was observed for 4 weeks, allowing comparison of initial fibrosis formation and debrided groups. The following salient observations were made: (i) debridement neither exacerbated nor ameliorated strength deficits; (ii) debridement results in recurrent fibrotic tissue deposition of a similar magnitude and composition as acute VML injury; and (iii) similarly upregulated transcriptional fibrotic and transcriptional pathways persist 4 weeks after initial VML or delayed debridement. This highlights the need for future studies to investigate adjunctive antifibrotic treatments for the fibrosed musculature.

UR - http://www.scopus.com/inward/record.url?scp=85035246479&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85035246479&partnerID=8YFLogxK

U2 - 10.1111/cts.12519

DO - 10.1111/cts.12519

M3 - Article

C2 - 29193769

AN - SCOPUS:85035246479

SN - 1752-8054

VL - 11

SP - 208

EP - 217

JO - Clinical and Translational Science

JF - Clinical and Translational Science

IS - 2

ER -

Inflammatory and Physiological Consequences of Debridement of Fibrous Tissue after Volumetric Muscle Loss Injury

Abstract

Bibliographical note

PubMed: MeSH publication types

Access

Other files and links

Fingerprint

Cite this